1289023-67-1 Usage
Description
BMS 927711 is a drug compound that is currently in development for the treatment of various medical conditions. It is a selective antagonist of the human 5-HT1F receptor, which plays a role in the modulation of migraine headaches. BMS 927711 has demonstrated efficacy in clinical trials for the acute treatment of migraine with or without aura in adults.
Uses
Used in Pharmaceutical Industry:
BMS 927711 is used as a drug compound for the acute treatment of migraine with or without aura in adults. It works by selectively blocking the human 5-HT1F receptor, which helps to alleviate migraine symptoms.
Used in Migraine Treatment:
BMS 927711 is used as a migraine treatment for providing relief from pain and the most bothersome symptoms associated with migraine attacks. In clinical trials, a single dose of BMS 927711 has shown superiority over placebo in achieving freedom from pain and freedom from the most bothersome symptom at 2 hours post-dose.
Check Digit Verification of cas no
The CAS Registry Mumber 1289023-67-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,8,9,0,2 and 3 respectively; the second part has 2 digits, 6 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1289023-67:
(9*1)+(8*2)+(7*8)+(6*9)+(5*0)+(4*2)+(3*3)+(2*6)+(1*7)=171
171 % 10 = 1
So 1289023-67-1 is a valid CAS Registry Number.
1289023-67-1Relevant articles and documents
Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
-
, (2015/01/18)
The invention relates to a packaging comprising one or more administration units comprising a solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione.
PROCESS FOR THE PREPARATION OF CYCLOHEPTAPYRIDINE CGRP RECEPTOR ANTAGONISTS
-
, (2012/05/04)
The disclosure generally relates to a process for the preparation of compounds of formula (I), including synthetic intermediates which are useful in the process.
CGRP RECEPTOR ANTAGONISTS
-
, (2011/05/05)
The disclosure generally relates to the novel compounds of formula (I), including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).